News
Lilly's GLP-1s race away in Q2, though Foundayo falls short
Eli Lilly has posted another record quarter of revenue growth, up 48% to $23bn, with Mounjaro and Zepbound now making up two-thirds of the total.
Wednesday 23 September 2026
